CL2012003105A1 - Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal. - Google Patents

Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.

Info

Publication number
CL2012003105A1
CL2012003105A1 CL2012003105A CL2012003105A CL2012003105A1 CL 2012003105 A1 CL2012003105 A1 CL 2012003105A1 CL 2012003105 A CL2012003105 A CL 2012003105A CL 2012003105 A CL2012003105 A CL 2012003105A CL 2012003105 A1 CL2012003105 A1 CL 2012003105A1
Authority
CL
Chile
Prior art keywords
composition
bacterium
female
pregnancy
expresses
Prior art date
Application number
CL2012003105A
Other languages
English (en)
Inventor
Rachel Teitelbaum
Original Assignee
Hervana Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44718589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003105(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hervana Ltd filed Critical Hervana Ltd
Publication of CL2012003105A1 publication Critical patent/CL2012003105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/14—Female reproductive, genital organs
    • A61M2210/1475—Vagina
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bacteria comensal genéticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composición que comprende dicha bacteria; uso de dicha composición para la reducción de la incidencia de embarazo en una población femenina; dispositivo de inserción intravaginal.
CL2012003105A 2010-05-06 2012-11-06 Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal. CL2012003105A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33189210P 2010-05-06 2010-05-06
IL208820A IL208820A0 (en) 2010-10-19 2010-10-19 Biologic female contraceptives

Publications (1)

Publication Number Publication Date
CL2012003105A1 true CL2012003105A1 (es) 2013-03-15

Family

ID=44718589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003105A CL2012003105A1 (es) 2010-05-06 2012-11-06 Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.

Country Status (22)

Country Link
US (1) US8668903B2 (es)
EP (1) EP2566490B1 (es)
JP (3) JP2013527763A (es)
KR (1) KR101927747B1 (es)
CN (2) CN102971007A (es)
AP (1) AP2012006598A0 (es)
AU (2) AU2011249472B2 (es)
BR (1) BR112012028427A2 (es)
CA (1) CA2797082C (es)
CL (1) CL2012003105A1 (es)
CO (1) CO6640222A2 (es)
EA (1) EA201291177A1 (es)
ES (1) ES2671345T3 (es)
IL (2) IL208820A0 (es)
MX (1) MX2012012576A (es)
NZ (1) NZ603450A (es)
PE (1) PE20130577A1 (es)
PH (1) PH12012502197A1 (es)
SG (1) SG185453A1 (es)
TR (1) TR201807468T4 (es)
WO (1) WO2011138776A2 (es)
ZA (1) ZA201208328B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20230002785A1 (en) * 2019-10-28 2023-01-05 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
CN110934895A (zh) * 2019-12-26 2020-03-31 南昌大学 卷曲乳酸杆菌用于制备女性避孕药物的应用
CN118681064A (zh) * 2024-05-31 2024-09-24 华中科技大学同济医学院附属协和医院 一种基于聚多巴胺-壳聚糖衣康酸层层自组装的抗钙化生物瓣及其制备方法与应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4322399A (en) 1979-10-19 1982-03-30 Ortho Pharmaceutical Corporation Vaginal suppository
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4693705A (en) 1984-04-09 1987-09-15 Gero Ilona B Vaginal contraceptive system
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
JPS61210285A (ja) 1985-03-14 1986-09-18 Toshiba Corp 回転式圧縮機
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5227160A (en) 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
US4922928A (en) 1988-08-17 1990-05-08 Michael Burnhill Vaginal device
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5602005A (en) 1989-03-03 1997-02-11 The University Of Virginia Alumni Patents Foundation Primate intra-acrosomal sperm antigen for use in a contraceptive vaccine
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JP3626181B2 (ja) * 1992-03-13 2005-03-02 ザ ロックフェラー ユニバーシティー グラム陽性菌の表面上のハイブリッド表面タンパク質の供給及び発現
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
ES2136664T3 (es) 1992-06-09 1999-12-01 Hoppe Ag Sistema de cierre y conjunto de cerradura.
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
ZA947572B (en) 1993-09-29 1995-09-28 Hampton Roads Medical College Contraceptive compositions
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830472A (en) 1996-06-28 1998-11-03 The University Of Virginia Patent Foundation Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
AU3196099A (en) 1998-03-27 1999-10-18 President And Fellows Of Harvard College Systematic identification of essential genes by (in vitro) transposon mutagenesis
ATE423215T1 (de) 1998-03-31 2009-03-15 Takara Bio Inc Verfahren zur herstellung von lysosphingolipiden
AU776288B2 (en) * 1998-10-05 2004-09-02 Regents Of The University Of California, The Methods and adjuvants for stimulating mucosal immunity
AU7131600A (en) 1999-06-21 2001-01-09 North Carolina State University Acid-inducible promoters for gene expression
WO2001007083A1 (en) 1999-07-23 2001-02-01 University Of Virginia Patent Foundation Recombinant antibody directed against human sperm antigen
US7179458B2 (en) 2002-03-08 2007-02-20 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
US7754467B2 (en) * 2003-01-29 2010-07-13 Osel, Inc. Surface expression of biologically active proteins in bacteria
US20050191318A1 (en) * 2004-02-27 2005-09-01 Kitto G. B. DNA immunocontraceptive vaccines and uses thereof
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide
ATE511848T1 (de) * 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
ATE437185T1 (de) * 2005-03-25 2009-08-15 Univ Ramot Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
WO2006104890A2 (en) * 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
WO2009062034A1 (en) * 2007-11-07 2009-05-14 Auburn University Methods, compositions, and sequences of zp-binding peptides for immunocontraception of dogs and other animals
CN103293689B (zh) 2013-05-31 2015-05-13 京东方科技集团股份有限公司 一种可在不同显示模式之间切换的方法和显示装置

Also Published As

Publication number Publication date
ZA201208328B (en) 2013-07-31
CA2797082C (en) 2023-12-05
EA201291177A1 (ru) 2013-06-28
BR112012028427A2 (pt) 2017-03-21
PE20130577A1 (es) 2013-05-19
US8668903B2 (en) 2014-03-11
SG185453A1 (en) 2012-12-28
CN107058199B (zh) 2025-11-18
WO2011138776A2 (en) 2011-11-10
US20130045184A1 (en) 2013-02-21
AU2011249472A1 (en) 2012-12-13
CA2797082A1 (en) 2011-11-10
TR201807468T4 (en) 2018-07-23
CO6640222A2 (es) 2013-03-22
EP2566490A2 (en) 2013-03-13
JP7195826B2 (ja) 2022-12-26
EP2566490A4 (en) 2014-03-05
JP2017012192A (ja) 2017-01-19
NZ603450A (en) 2015-10-30
EP2566490B1 (en) 2018-02-28
ES2671345T3 (es) 2018-06-06
JP2013527763A (ja) 2013-07-04
PH12012502197A1 (en) 2013-02-25
JP2019017389A (ja) 2019-02-07
KR20130117646A (ko) 2013-10-28
AP2012006598A0 (en) 2012-12-31
KR101927747B1 (ko) 2018-12-12
IL208820A0 (en) 2011-01-31
MX2012012576A (es) 2013-03-18
IL222836A0 (en) 2012-12-31
AU2015252159A1 (en) 2015-11-26
AU2015252159B2 (en) 2017-07-20
CN107058199A (zh) 2017-08-18
AU2011249472B2 (en) 2015-11-26
CN102971007A (zh) 2013-03-13
WO2011138776A3 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CL2012003105A1 (es) Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
PE20142239A1 (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
CL2011003113A1 (es) Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica.
BR112018007546A2 (pt) dispositivo e sistema tridimensional para alívio do prolapso
CL2012001019A1 (es) Composicion farmaceutica que comprende una proenzima de proteasa seleccionada de al menos tripsinogeno y quimiotripsinogeno y un agente activo seleccionado de al menos un compuesto de selenio, un compuesto vanilloide, un agente reductor de glicolisis citoplasmica y opcionalmente una glucosidohidrolasa; y uso para tratar cancer.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
ECSP13012382A (es) Composiciones sólidas
CL2008001984A1 (es) Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero.
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
CL2012000955A1 (es) Empalmadora de cintas comprende: una primera y segunda mordaza de sujecion en una relacion enfrentada, con un medio conectado a la primera y segunda morzada para liberar rapidamente dichas mordazas funciona para dirigir un impulso de fuerza contra la primera y segunda mordaza; y metodo.
BR112015002517A8 (pt) método para ajudar na concepção, método para transferência de sêmen e método para transferir sêmen a partir de um dispositivo”.
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
BR112015012453A8 (pt) métodos e usos para sincronizar o tempo de ovulação e de inseminação em uma leitoa
MX2016008387A (es) Dispositivo de apertura de pacas.
CL2008003768A1 (es) Aparato para transformar el movimiento de las olas en movimiento reciprocante, que comprende un actuador flotante ubicado entre y por sobre dispositivos con accion reciprocante conectados al actuador flotante.
CL2011003080A1 (es) Composicion fungicida que comprende tolclofos-metilo, fosfato de polioxietilen poliarilfenol, copolimero de bloque de polioxietileno polioxipropileno, eter de alcohol graso de polioxietileno y agua.
AR085200A1 (es) MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
MX353172B (es) Sistema y método para control de embrión.
AR106926A1 (es) Método para reducir la formación de anticuerpos anti-fármaco (ada) y método de tratamiento de un trastorno proliferativo de celulas b